Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ: TEM) has launched Notetaker, an AI-powered clinical assistant designed to help psychiatrists generate progress notes. The tool, available through Tempus Hub, automatically records and transcribes patient sessions, creating clinical notes that integrate with electronic health records. Notetaker features real-time transcription with specialized psychiatric terminology recognition, automatic clinical note generation, and care gap notifications with pharmacogenomic insights.
The platform supports over 30 languages including English, Spanish, and Chinese, with automatic language switching capabilities. It complements Tempus' existing mental health solutions, including the Tempus nP pharmacogenomic test and PRO™ patient reported outcome solution. The HIPAA-compliant system offers adjustable settings for telehealth, in-person sessions, and dictation.
Tempus has published a validation study in the Journal of Molecular Diagnostics showcasing the effectiveness of its xF+ liquid biopsy assay. The study confirms that xF+ serves as a non-invasive method to detect actionable variants, identify biomarkers, and monitor disease progression.
Key highlights of the xF+ assay include:
- Coverage of 523 genes spanning ~1.8 Mb of the human genome
- Integration with Tempus multimodal database
- Demonstrated concordance with Tempus xF and xT assays for MSI status
- Proven accuracy, sensitivity, specificity, and precision
Originally launched in 2022, xF+ stands as one of the largest clinically available liquid biopsy panels for physicians. The validation process involved clinical samples, reference standards, synthetic cell lines, and healthy control samples.
Tempus AI (NASDAQ: TEM) has unveiled Tempus Loop, an innovative oncology-focused platform for target discovery and validation. The platform integrates real-world patient data (RWD), human-derived biological models, and CRISPR-screens with AI to accelerate pre-clinical therapeutic development.
Loop addresses a critical industry challenge where conventional approaches using cell lines or animal models often fail to reliably represent human tumors. The platform identifies patient subpopulations with similar clinical patterns and uses systems biological approaches to reveal novel target genes. It leverages patient-derived organoids (PDOs) for validation, ensuring closer reflection of patient attributes.
The platform has already demonstrated success, helping a large pharmaceutical company prioritize drug targets in patient subpopulations with unmet needs, validating targets within a year. According to Chief Scientific Officer Kate Sasser, PhD, this approach aims to improve the current 90% failure rate for preclinical assets becoming real-world medicines.
Tempus AI (NASDAQ: TEM) announced the acceptance of 18 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations include one oral and multiple poster sessions showcasing the company's AI-driven research in oncology.
Key research highlights include: 1) An oral presentation examining SF3B1 hotspot mutations in breast cancer, analyzing data from 420 patients; 2) A poster on NUTM1 structural variants, identifying 59 NUT carcinoma patients with an 81% NUTM1 fusion rate; 3) A study of 109 patients evaluating circulating tumor DNA as a biomarker for tyrosine kinase inhibitor therapy response; and 4) A collaborator-led presentation with T-knife Therapeutics on TCR-T therapy targeting PRAME-positive solid tumors.
Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025. The earnings conference call will be held at 4:30 p.m. ET on the same day.
The presentation will feature CEO Eric Lefkofsky and CFO Jim Rogers. Investors can access the live audio webcast through Tempus' Investor Relations website's events page or join via phone using the conference ID 4680302 (Domestic: 800-715-9871, International: 646-307-1963).
Tempus AI (NASDAQ: TEM) has announced multi-year strategic collaborations with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology. The partnerships will focus on:
- Gathering biological and clinical insights
- Discovering novel drug targets
- Developing therapeutics for the oncology community
The agreements include $200 million in data licensing and model development fees to Tempus. The collaboration expands on Tempus' existing 2021 partnership with AstraZeneca, utilizing Tempus' AI-enabled platform and multimodal data repository to advance therapeutic programs in oncology globally. The foundation model will be built using Tempus' de-identified oncology data and will be shared among all three parties to enhance their respective patient care initiatives.
Tempus AI (NASDAQ: TEM) has announced the formation of its Advisory Board, comprising distinguished physicians from leading medical institutions across the United States. The board will provide strategic guidance on research, product development, and clinical utility of Tempus's AI-enabled platform for precision medicine.
Led by Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, the advisory board includes 13 renowned medical professionals specializing in various oncology fields. Notable members include directors and professors from prestigious institutions such as Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic, and Vanderbilt-Ingram Cancer Center.
The advisory board's primary focus will be maintaining high standards and ensuring the company's strategy remains grounded in expert knowledge, supporting Tempus's mission of advancing precision medicine and patient care through AI technology.